Di Maria Jiang1, Peter Chung2, Girish S Kulkarni3, Srikala S Sridhar4. 1. Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Canada, 700 University Avenue, Toronto, ON, Canada. 2. Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network, University of Toronto, Canada, 700 University Ave, Toronto, ON, Canada. 3. Departments of Surgery and Surgical Oncology, Division of Urology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Canada, 6-824, 700 University Avenue, Toronto, ON, Canada. 4. Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Canada, 700 University Avenue, Toronto, ON, Canada. srikala.sridhar@uhn.ca.
Abstract
PURPOSE OF REVIEW: Bladder-sparing trimodality therapy (TMT) has become an accepted alternative to cystectomy for selected muscle invasive bladder cancer (MIBC) patients unfit for cystectomy or opting for bladder preservation. This review will summarize recent advances in TMT for MIBC. RECENT FINDINGS: A growing body of literature has emerged which supports the use of TMT. However, its delivery is yet to be standardized. The role of chemotherapy and predictive biomarkers remain to be elucidated. Novel bladder-sparing approaches, drug combinations including immunotherapy and targeted therapies are under investigation in clinical trials, with the goal of ultimately enhancing survival and quality of life outcomes. Recent advances in TMT have made bladder preservation possible for MIBC patients seeking an alternative local therapy to cystectomy. With careful patient selection, TMT offers comparable survival outcomes to cystectomy, and improved quality of life as patients are able to successfully retain their bladder.
PURPOSE OF REVIEW: Bladder-sparing trimodality therapy (TMT) has become an accepted alternative to cystectomy for selected muscle invasive bladder cancer (MIBC) patients unfit for cystectomy or opting for bladder preservation. This review will summarize recent advances in TMT for MIBC. RECENT FINDINGS: A growing body of literature has emerged which supports the use of TMT. However, its delivery is yet to be standardized. The role of chemotherapy and predictive biomarkers remain to be elucidated. Novel bladder-sparing approaches, drug combinations including immunotherapy and targeted therapies are under investigation in clinical trials, with the goal of ultimately enhancing survival and quality of life outcomes. Recent advances in TMT have made bladder preservation possible for MIBC patients seeking an alternative local therapy to cystectomy. With careful patient selection, TMT offers comparable survival outcomes to cystectomy, and improved quality of life as patients are able to successfully retain their bladder.
Authors: Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Simone Bertz; S Wach; H Taubert; R Merten; F S Krause; S Schick; O J Ott; E Weigert; O Dworak; C Rödel; R Fietkau; B Wullich; B Keck; A Hartmann Journal: Virchows Arch Date: 2016-07-08 Impact factor: 4.064
Authors: Jason A Efstathiou; Daphna Y Spiegel; William U Shipley; Niall M Heney; Donald S Kaufman; Andrzej Niemierko; John J Coen; Rafi Y Skowronski; Jonathan J Paly; Francis J McGovern; Anthony L Zietman Journal: Eur Urol Date: 2011-11-12 Impact factor: 20.096
Authors: R E Jimenez; M Hussain; F J Bianco; U Vaishampayan; P Tabazcka; W A Sakr; J E Pontes; D P Wood; D J Grignon Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: Ananya Choudhury; Louisa D Nelson; Mark T W Teo; Sameer Chilka; Selina Bhattarai; Colin F Johnston; Faye Elliott; Johanna Lowery; Claire F Taylor; Michael Churchman; Johanne Bentley; Margaret A Knowles; Patricia Harnden; Robert G Bristow; D Timothy Bishop; Anne E Kiltie Journal: Cancer Res Date: 2010-09-15 Impact factor: 12.701
Authors: Michael P Hagan; Kathryn A Winter; Donald S Kaufman; Zev Wajsman; Anthony L Zietman; Naill M Heney; Leonard M Toonkel; Christopher U Jones; John D Roberts; William U Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-01 Impact factor: 7.038
Authors: Matthew C Knox; Jie Ni; Andrej Bece; Joseph Bucci; Yaw Chin; Peter H Graham; Yong Li Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561